量子高科（中国）生物股份有限公司 2016 年第三季度报告全文 量子高科（中国）生物股份有限公司 2016 年第三季度报告 2016 年 10 月 1 量子高科（中国）生物股份有限公司 2016 年第三季度报告全文 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资 料不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担个别及连带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人曾宪经、主管会计工作负责人黎定辉及会计机构负责人(会计主 管人员)王凤容声明：保证季度报告中财务报告的真实、完整。 2 量子高科（中国）生物股份有限公司 2016 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末 | | --- | --- | --- | --- | --- | | | | | | 增减 | | 总资产（元） | 778,329,224.42 | 756,003,841.3 ...

Financial Performance - Total revenue for the first half of 2016 was CNY 122,910,401.91, a decrease of 26.67% compared to CNY 167,609,426.24 in the same period last year[18]. - Net profit attributable to ordinary shareholders increased by 28.06% to CNY 31,961,269.07, up from CNY 24,958,244.46 year-on-year[18]. - Basic earnings per share rose by 28.81% to CNY 0.076, compared to CNY 0.059 in the same period last year[18]. - The company achieved total operating revenue of RMB 122.91 million in the first half of 2016, a decrease of 26.67% year-on-year, primarily due to the exclusion of Shenghetang from the consolidated financial statements after the sale of a 10% stake in August 2015[32]. - Net profit attributable to ordinary shareholders was RMB 31.96 million, a year-on-year increase of 28.06%, driven by stable revenue growth and a higher proportion of high-value-added products[32]. - The company reported a total of CNY 3,901,135.17 in non-recurring gains and losses during the reporting period[20]. - The company reported a significant increase in investment income, which rose to ¥4,402,120.79 from ¥2,299,056.85, marking a growth of 91.3%[134]. - The company reported a net profit of ¥2,698,457.67 from its major associate company, Guangdong Shenghetang Health Food, which has been actively increasing market promotion efforts[52]. Cash Flow and Liquidity - Net cash flow from operating activities decreased by 43.51% to CNY 34,344,746.25, compared to CNY 60,796,167.99 in the previous year[18]. - The company’s cash and cash equivalents increased by 93.62% to CNY 96.95 million, attributed to growth in operating income and the maturity of bank financial products[38]. - The cash flow from investment activities showed a net inflow of ¥33,683,538.73, a significant recovery from a net outflow of ¥99,428,966.86 in the previous period[139]. - The company’s cash management strategy involved idle self-owned funds and raised funds, with no overdue principal or interest amounts reported[78]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 761,069,085.88, an increase of 0.67% from CNY 756,003,841.36 at the end of the previous year[18]. - The total current liabilities decreased to CNY 22,282,292.99 from CNY 30,216,339.12, a reduction of approximately 26.4%[125]. - The total liabilities decreased to CNY 24,175,771.16 from CNY 32,194,351.41, a reduction of approximately 25%[125]. - The company’s total equity increased to CNY 737,680,503.58 from CNY 723,927,669.79, reflecting a growth of 1.9%[129]. Research and Development - Research and development expenses amounted to RMB 6.23 million, representing 5.07% of operating revenue, with a focus on maintaining core technology leadership in prebiotics[32]. - Research and development expenses decreased by 17.21% to CNY 6.23 million, indicating a potential shift in focus or resource allocation[38]. Market Strategy and Competition - The company aims to expand its market presence and customer base in response to intensified competition in the prebiotic industry[26]. - The company is committed to enhancing brand recognition and product quality to maintain its competitive position in the prebiotic market[29]. - The company plans to mitigate raw material price fluctuations by engaging in sugar futures hedging and improving production processes to reduce raw material consumption[24]. Shareholder and Equity Information - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company has committed to avoiding related party transactions and ensuring fair trading practices[98]. - The company’s major shareholders have made commitments regarding the transfer of shares, limiting annual transfers to no more than 25% of their holdings[98]. - The company reported a net profit distribution to shareholders of 21,105,000.00 yuan during the period[155]. Compliance and Governance - The company has not made any adjustments or restatements to previous years' accounting data[17]. - The financial statements are prepared based on the going concern principle, with no significant matters affecting the company's ability to continue as a going concern for at least 12 months from the reporting date[159]. - The company adheres to the Chinese Accounting Standards, ensuring that the financial statements accurately reflect its financial position, operating results, and cash flows[162]. Investment and Fundraising - The company reported a total fundraising amount of ¥47,600,000, with ¥25,079,610 already invested and a remaining balance of ¥22,730,830 as of June 30, 2016[61]. - The company raised RMB 47.6 million from its initial public offering, exceeding the planned fundraising amount by RMB 25.42 million[64]. - The total investment for the "Annual Production of 10,000 Tons of Oligofructose and Its Packaging Production Line Expansion Project" reached CNY 101.89 million, with a remaining balance of CNY 12.24 million in raised funds[65]. Operational Performance - The company maintained a 100% product qualification rate in the first half of 2016, reflecting enhanced quality awareness and responsibility among employees[33]. - The company has successfully developed six national standard products for oligosaccharides, filling a significant gap in the market and enhancing its core competitiveness[57]. - The company has been recognized as a high-tech enterprise in Guangdong Province, allowing it to benefit from a reduced corporate income tax rate of 15% until 2017[32].

量子高科（中国）生物股份有限公司 2016 年半年度报告全文 量子高科（中国）生物股份有限公司 2016 年半年度报告 第一节 重要提示、释义 本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料 不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性、完整性承担个别及连带责任。 所有董事均已出席了审议本报告的董事会会议。 公司负责人曾宪经、主管会计工作负责人黎定辉及会计机构负责人(会计主 管人员)王凤容声明：保证年度报告中财务报告的真实、准确、完整。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | 2016 年 08 月 1 量子高科（中国）生物股份有限公司 2016 年半年度报告全文 | 2016 | 半年度报告 1 | | --- | --- | | 第一节 | 重要提示、释义 2 | | 第二节 | 公司基本情况简介 5 | | 第三节 | 董事会报告 10 | | 第四节 | 重要事项 25 | | 第五节 | 股份变动及股东情况 32 | | 第六节 | 董事、监事、高级管理人员情况 36 | | 第七节 | 财务报告 38 | | 第八节 | ...

量子高科（中国）生物股份有限公司 2016 年第一季度报告全文 量子高科（中国）生物股份有限公司 2016 年第一季度报告 2016 年 04 月 1 量子高科（中国）生物股份有限公司 2016 年第一季度报告全文 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资 料不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担个别及连带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人曾宪经、主管会计工作负责人黎定辉及会计机构负责人(会计主 管人员)王凤容声明：保证季度报告中财务报告的真实、完整。 2 量子高科（中国）生物股份有限公司 2016 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 54,298,268.17 | 71,246,658.48 | -23.79% | | 归属于上市公司 ...

量子高科（中国）生物股份有限公司 2015 年年度报告全文 量子高科（中国）生物股份有限公司 公司负责人曾宪经、主管会计工作负责人黎定辉及会计机构负责人(会计主管人员)王凤 容声明：保证年度报告中财务报告的真实、准确、完整。 2015 年年度报告 2016 年 03 月 1 所有董事均已出席了审议本报告的董事会会议。 量子高科（中国）生物股份有限公司 2015 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成本公司对任何投资者 及相关人士的承诺，投资者及相关人士均应对此保持足够的风险认识，并且应当理解计划、 预测与承诺之间的差异。 非标准审计意见提示 □ 适用 √ 不适用 内部控制重大缺陷提示 □ 适用 √ 不适用 对年度报告涉及未来计划等前瞻性陈述的风险提示 √ 适用 □ 不适用 本公司请投资者认真阅读本年度报告全文，并特别注意下列风险因素： （1）产品质量风险 近年来国内食品安全问题频发，已经造成食品 ...

量子高科（中国）生物股份有限公司 2015 年第三季度报告全文 量子高科（中国）生物股份有限公司 2015 年第三季度报告 2015 年 10 月 1 量子高科（中国）生物股份有限公司 2015 年第三季度报告全文 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人曾宪经、主管会计工作负责人黎定辉及会计机构负责人(会计主管人员)王凤容声明：保证 季度报告中财务报告的真实、完整。 2 量子高科（中国）生物股份有限公司 2015 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末 | | --- | --- | --- | --- | --- | | | | | | 增减 | | 总资产（元） | 757,142,739.56 | | 741,128,471. ...

Financial Performance - Total revenue for the first half of 2015 was CNY 167,609,426.24, representing a 19.93% increase compared to CNY 139,760,359.27 in the same period last year[18]. - Net profit attributable to ordinary shareholders was CNY 24,958,244.46, up 34.61% from CNY 18,541,217.21 year-on-year[18]. - Net cash flow from operating activities reached CNY 60,796,167.99, a significant increase of 97.23% compared to CNY 30,824,618.65 in the previous year[18]. - Basic earnings per share rose to CNY 0.06, reflecting a 50.00% increase from CNY 0.04 in the same period last year[18]. - The net profit after deducting non-recurring gains and losses was CNY 22,838,019.79, an increase of 27.70% from CNY 17,884,363.47 year-on-year[18]. - The company achieved operating revenue of ¥167.61 million, a year-on-year increase of 19.93%[35]. - The company reported a gross profit margin of approximately 45.5%, calculated from total operating revenue and total operating costs[130]. - The total comprehensive income for the first half of 2015 was 25,220,444.89 CNY, reflecting the same amount as the net profit, indicating no other comprehensive income items were recorded[134]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 769,261,737.35, a 3.80% increase from CNY 741,128,471.88 at the end of the previous year[18]. - The company's total liabilities rose to CNY 59,565,451.95 from CNY 44,602,037.43, representing an increase of about 33.5%[122]. - The company's equity increased significantly, with the share capital rising to CNY 422,100,000.00 from CNY 301,500,000.00, marking a growth of approximately 40%[122]. - The total amount of retained earnings at the end of the period was 174,000,000[152]. Investments and Expenditures - R&D expenditure for the first half of 2015 was 7.52 million yuan, an increase of 5.29% compared to the same period last year[31]. - The company has a total of CNY 47,600 million in raised funds, with CNY 166.39 million invested during the reporting period and a remaining balance of CNY 22,430.40 million as of June 30, 2015[54]. - The total actual investment for the "10,000 tons of fructooligosaccharides and packaging production line expansion project" reached CNY 101.89 million, with a remaining balance of CNY 12.24 million in raised funds[59]. Strategic Initiatives - The company signed a strategic cooperation agreement with Shanghai Quanjia Kangjian Electronic Technology Co., Ltd. to promote the health business of its terminal product, Aliguo[32]. - The company aims to mitigate risks from raw material price fluctuations by engaging in sugar futures hedging and improving production processes to reduce raw material consumption[24]. - The company is expanding into the B2C market through its subsidiary, facing risks in brand marketing and product development[26]. - The company plans to enhance its brand recognition and explore new product application areas to maintain its competitive edge in the probiotics industry[27]. Shareholder and Equity Information - The company implemented a profit distribution plan for the 2014 fiscal year, distributing RMB 0.40 per 10 shares in cash and increasing capital by 4 shares for every 10 shares held[71]. - The total number of shareholders at the end of the reporting period was 17,884[107]. - Quantum Hi-Tech Group Limited holds 24.09% of shares, totaling 101,696,176 shares, with an increase of 29,056,051 shares during the reporting period[107]. - The company’s shareholding structure includes 33.82% of restricted shares and 66.18% of unrestricted shares[102]. Compliance and Governance - The company has not reported any changes in the use of raised funds during the reporting period[60]. - The financial report was approved by the board of directors on August 13, 2015[155]. - The company adheres to the Chinese Accounting Standards and ensures that its financial statements reflect a true and complete picture of its financial status[158]. Market Position and Product Development - The company is recognized as a leading entity in the micro-ecological field and has established itself as a pioneer in the Chinese market for oligosaccharides, with a comprehensive product line[49]. - The company’s main products, oligosaccharides, align with the growing consumer trend towards health-oriented products, indicating a strong market potential[48]. - The company’s first terminal product, "Ali Guo," has been launched, marking its entry into the prebiotic end-product market[49].

量子高科（中国）生物股份有限公司 2015 年第一季度报告全文 量子高科（中国）生物股份有限公司 2015 年第一季度报告 2015 年 04 月 1 量子高科（中国）生物股份有限公司 2015 年第一季度报告全文 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资 料不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担个别及连带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王丛威、主管会计工作负责人黎定辉及会计机构负责人(会计主 管人员)王凤容声明：保证季度报告中财务报告的真实、完整。 2 量子高科（中国）生物股份有限公司 2015 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 否 | | 本报告期 | 上年同期 | 本报告期比上年同 | | --- | --- | --- | --- | | | | | 期增减 | | 营业总收入（元） | 71,246,658.48 | 57,751,958.27 | 23.37% | | 归属于 ...

量子高科（中国）生物股份有限公司 2014 年年度报告全文 量子高科（中国）生物股份有限公司 2014 年年度报告 2015 年 04 月 0 量子高科（中国）生物股份有限公司 2014 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料 不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性和完整性承担个别及连带责任。 所有董事均已出席了审议本报告的董事会会议。 公司负责人王丛威、主管会计工作负责人黎定辉及会计机构负责人(会计主 管人员)王凤容声明：保证年度报告中财务报告的真实、准确、完整。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成本公司 对任何投资者及相关人士的承诺，投资者及相关人士应对此保持足够的风险认 识，并且应当理解计划、预测与承诺之间的差异。 1 | 第一节 | 重要提示、目录和释义 1 | | --- | --- | | 第二节 | 公司基本情况简介 4 | | 第三节 | 会计数据和财务指标摘要 6 | | 第四节 | 董事会报告 10 | | 第五节 | 重要事项 35 | | 第六节 | 股份变 ...

量子高科（中国）生物股份有限公司 2014 年第三季度报告全文 量子高科（中国）生物股份有限公司 2014 年第三季度报告 2014 年 10 月 1 量子高科（中国）生物股份有限公司 2014 年第三季度报告全文 公司负责人王丛威、主管会计工作负责人黎定辉及会计机构负责人(会计主管人员)王凤容声明：保证 季度报告中财务报告的真实、完整。 2 量子高科（中国）生物股份有限公司 2014 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增 | | --- | --- | --- | --- | --- | | | | | | 减 | | 总资产（元） | 733,045,148.40 | | 703,988,366.99 | 4.13% | | 归属于上市公司普通股股东的 | 669,233,748.49 | | 646,593,766.17 | 3.50% | | 股东权益（元） | | | | | | 归属于上市公司普通股股东的 | 2.2197 | ...